Inclusion Criteria : 
  1.  Histologically diagnosed high - grade serous or endometrioid ovarian cancer ( including primary peritoneal and fallopian tube cancer ) 
  2.  Completion of ≥ 2 previous platinum - containing regimens
  3.  Complete response ( CR ) or partial response ( PR ) achieved with last platinum - based chemotherapy regimen as determined by investigator
  4.  Ability to be randomized ≤ 8 weeks after last dose of platinum
Exclusion Criteria : 
  1.  Prior treatment with a poly ( ADP - ribose ) polymerase ( PARP ) inhibitor
  2.  Patients who have received other study drug treatment within 4 weeks prior to the first administration (  < 5 elimination half - lives of the study drug molecular targeted anti - cancer drugs ) . 
  3.  Patients with clinical symptoms of cancer ascites , pleural effusion , who need to drainage , or who have undergone ascites drainage within 2 months prior to the first administration.